

06/26/01

06-27-01

jc99 Please type a plus sign (+) inside this box.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

Patent

Attorney Docket No. PC10877A

First Named Inventor or Application Identifier T. Kaneko

Title MACROLIDE ANTIBIOTICS

Express Mail Label No. EL446402369US

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)ADDRESS TO: Commissioner for Patents  
Box Patent Application  
Washington, DC 202312.  Specification [Total Pages 25] ]6.  Microfiche Computer Program (Appendix)  
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference in Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.  Drawing(s) (35 U.S.C. 11.3) [Total sheets ]4.  Oath or Declaration [Total pages 3] ]

- a.  Newly executed (original or copy)
- b.  Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 17 completed)  
**[Note Box 5 below]**
- i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 C.F.R. §§1.63(d)(2) and 1.33(b).

5.  Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a  
copy of the oath or declaration is supplied under Box 4b, is  
considered to be part of the disclosure of the accompanying  
application and is hereby incorporated by reference therein.**ACCOMPANYING APPLICATION PARTS**

- 8.  Assignment Papers (cover sheet & document(s))
- 9.  37 C.F.R. §3.73(b) Statement  Power of Attorney  
(when there is an assignee)
- 10.  English Translation Document (if applicable)
- 11.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS  
Citations
- 12.  Preliminary Amendment
- 13.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- 14.  \*Small Entity  Statement filed in prior application,  
Statement(s) Status still proper and desired  
(PTO/SB/09-12)
- 15.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- 16.  Other: Priority Claim  
60/215,237  
filed June 30,2000

**\*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: /

Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

**18. CORRESPONDENCE ADDRESS**

(Insert Customer No. or Attach bar code label here)

or  Correspondence address below

Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939

NAME (Print/type)	SETI H. JACOBS	Registration No. (Attorney/Agent)	32,140
Signature	<i>Seti H. Jacobs</i>	Date	6-26-01

23913  
PATENT TRADEMARK OFFICE

UTILITY TRANSMITTAL PTO SB 05, 3/99, (1/1)

JC99 U.S. PRO 06/26/01

06/26/01

06/26/01  
1991 U.S. PTO  
**FEET TRANSMITTAL**

Patent fees are subject to annual revision on October 1.  
These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement,  
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

**Total Amount of Payment** **(\$)** **710.00**

Complete If Known

Application Number	Unassigned
Filing Date	Concurrent herewith
First Named Inventor	T. Kaneko
Examiner Name	Unassigned
Group/Art Unit	Unassigned
Attorney Docket No.	PC 10877A

**METHOD OF PAYMENT** (check one)

1.  The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number **16-1445**

Deposit Account Name **Pfizer Inc**

Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17.  Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2.  **Payment Enclosed:**

Check  Money Order  Other


**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity	Small Entity				
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge – late fee or oath	
127	50	227	25	Surcharge—late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					
*Reduced by Basic Filing Fee Paid				<b>SUBTOTAL (3) (\$)</b>	

**SUBTOTAL (2) (\$)** **0**

**SUBTOTAL (3) (\$)**

**SUBMITTED BY**

Type or Printed Name	SETH H. JACOBS	Complete (if Applicable)
Signature		Reg. Number <b>32,140</b>
	Date <b>6/26/01</b>	Deposit Account User ID



**23913**

PATENT TRADEMARK OFFICE

**CERTIFICATE OF MAILING - EXPRESS MAIL**

PFIZER DOCKET NO: PC10877A

## **TITLE: Macrolide Antibiotics**

APPLICANT: Richard D. Hedde.

"Express Mail" mailing label number EL446402369US

Date of Deposit June 26, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Michelle Dungee

(Typed or printed name of person mailing paper or fee)

Michelle Dungee  
(Signature of person mailing paper or fee)

Pfizer Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755